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SUMMARY
Between 1992 and 1997, 790 blood donors with anti-HCV EIA-2 strongly reagent (relationship between the sample optical
density/cut-off > 3) detected at the blood bank serological screening, were evaluated in ambulatory environment. They were all
negative for Chagas disease, syphilis, hepatitis B (HBsAg) and AIDS. Blood samples were collected at the first ambulatorial evaluation,
for hemogram, biochemical tests and new serological tests for HCV (anti-HCV EIA-2). In blood samples of 226 repeatedly reagent
anti-HCV EIA-2 blood donors, supplementary “immunoblot” test for HCV (RIBA-2) was used. In 209 donors, the presence of HCV-
RNA was investigated by the PCR test. The abdominal ultrasonography was realized in 366 donors. In 269 patients liver biopsy was
performed for the histopathological study. The follow-up of blood donors showed that 95.6% were repeatedly EIA-2 reagent, 94%
were symptomless and denied any hepatitis history, with only 2% mentioning previous jaundice. In 47% of this population at least
one risk factor has been detected for the HCV transmission, the use of intravenous drugs being the main one (27.8%). Blood transfusion
was the second factor for HCV transmission (27.2%). Hepatomegaly was detected in 54% of the cases. Splenomegaly and signs of
portal hypertension have seldom been found in the physical examination, indicating a low degree of hepatic compromising in HCV.
Abdominal ultrasound showed alterations in 65% of the subjects, being the steatosis the most frequent (50%). In 83.5% of the donors
submitted to the liver biopsy, the histopathological exam showed the presence of chronic hepatitis, usually classified as active (89%)
with mild or moderate grade in most of the cases (99.5%). The histopathological exam of the liver was normal in 1.5% of blood
donors. The RIBA-2 test and the HCV-RNA investigation by PCR were positive in respectively 91.6 and 75% of the anti-HCV EIA-
2 reagent donors. The HCV-RNA research was positive in 82% of the RIBA-2 positive subjects, in 37.5% of the indeterminate RIBA-
2 donors and in 9% of the negative RIBA-2 donors. Chronic hepatitis has also been observed in 50% of the histopathological exams
of the anti-HCV EIA-2 reagent donors which were indeterminate RIBA-2. Among 18 blood donors with minimal changes
histopathological exam 11 (61%) were HCV-RNA positive. Our blood donors anti-HCV reagent generally had clinical, laboratorial
and histopathological features observed in patients with chronic HCV hepatitis and a high proportion could be identified in interviews
and medical evaluation realized in blood blanks. Generally, these HCV infected donors are identified and discharged only by the
serological tests results.
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INTRODUCTION
Since the cloning and characterization of hepatitis C virus (HCV)7,
several studies have confirmed that HCV is the principal agent of post-
transfusional hepatitis around the world9,14,18. Blood transfusions, the
use of illicit drugs or, more rarely, organ transplants are the most common
pathways of HCV transmission5. About 18% to 26% of the patients with
HCV develop jaundice during the acute phase of the infection10 . In the
remaining cases, the patients show no symptoms12. About 85% of
individuals with HCV become chronically infected1,12 and the evolution
to chronic hepatitis (CH) usually passes imperceived12. Approximately
70% of the patients chronically infected with HCV have a persistent
elevation of hepatic enzymes1 and liver biopsies generally show
histological evidence of mild CH8,17,22,23. The routine screening of blood
donors has led to the identification of individuals with anti-HCV
antibodies who are asymptomatic and have no history of liver disease or
of exposure to risk factors for viral hepatitis. However, the clinical
significance of anti-HCV antibodies in these otherwise healthy persons
is unclear23. In this study, we investigated the laboratorial,
ultrassonographic, histological and epidemiological alterations in anti-
HCV blood donors and attempted to correlate these with the progress of
the infection.
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MATERIALS AND METHODS
Seven hundred and ninety consecutive blood donors attending the
Hemocenter at Unicamp, Campinas, SP State, Brazil, between April 1992
and December 1997 who were positive at least twice in the anti-HCV
EIA-2 test were referred to the Study Group of the Viral Hepatitis in the
Discipline of Transmissible Diseases of Faculty of Medical Sciences,
Unicamp. All donors had an EIA-2 ratio >3 (expressed as the optical
density of the test sample divided by the cutoff value). The result was
considered a low positive when the EIA ratio was <3 and a high positive
when the ratio was >3. All donors were negative for Chagas disease,
syphilis and AIDS. Individuals who were HBsAg positive were excluded.
Of the 790 blood donors, 699 (88%) were men and 91 (12%) women
with ages ranging from 18 to 60 years old (mean of 33 years). Most
(709, 90%) were white and the remaining (81, 10%), black. The donors
were interviewed using a standard questionnaire designed to identify a
series of parameters, including known risk factors for HCV infection
such as previous blood transfusion, intravenous drug use (IVDU),
acupuncture, tattoos, sexual or social contacts with icteric persons, the
presence of symptoms related to viral hepatitis, jaundice and sexual
habits. All donors underwent a complete physical examination. At the
first clinical evaluation, all donors were retested using the anti-HCV
EIA-2 assay (2nd. generation HCV EIA, Abbott Laboratories, North
Chicago, IL). Hemograms and hepatic biochemical determinations (ALT
and AST dosages and protein electrophoresis) were done four times a
year. Only donors with an EIA-2 ratio >3 continued in the follow-up.
HBV markers were also retested in 582 anti-HCV EIA-2 positive blood
donors at the first clinical evaluation with commercial kits: HBsAg
(AUSZYME MONOCLONAL, Abbott), anti-HBcAg (CORZYME,
Abbott) and anti-HBsAg (AUSAB, Abbott). ALT activity was determined
in serum by an automated assay (COBAS-MIRA, ROCHE) and the
normal values were 0-40 UI/l. The results were expressed as the ALT
quotient (qALT), calculated dividing the ALT level in the sample by the
maximum normal value for the method. When the ALT value was
elevated, qALT was always >1 RIBA II (4 antigens, ORTHO Diagnostics
Systems, Raritan, N.J.) were conducted in 226 donors. The result was
considered positive when the samples reacted with two or more proteins
of the kit, indeterminate when there was a reaction with only one of the
proteins and negative when there was no reaction with any protein. Two
hundred and nine donors were screened for HCV RNA by PCR (HCV-
AMPLICOR, ROCHE). Abdominal ultrasound (US) was performed in
366 anti-HCV EIA-2 positive blood donors and the diagnoses were
chronic hepatitis, steatosis, hepatomegaly, hepato and splenomegaly, liver
cirrhosis or normal liver. All donors 269 with a qALT>1 or with
hepatomegaly in the physical examination underwent a liver biopsy. The
diagnoses were normal liver (NL), chronic persistent hepatitis (CPH),
chronic active hepatitis (CAH), chronic lobular hepatitis (CLH), minimal
changes (MC), liver cirrhosis (LC) or other non-related lesions. Chronic
active hepatitis was mild, moderate or intense according periportal
activity. Statistical comparisons used the X2 or Fisher’s exact tests to
compare differences among groups. A p value ≤0.05 was considered
significant.
RESULTS
Anti-HCV EIA-2 prevalence. Seven hundred and fifty six patients
(95.6%) were anti-HCV EIA-2 positive, 17 (2.2%) were negative and
17 (2.2%) were anti-HCV indeterminate.
Epidemiological evaluation. One hundred and twenty two (16%)
anti-HCV positive donors reported previous social or sexual contact with
persons having viral hepatitis. Alcohol abuse was reported by 302/756
(40%) donors. HCV RNA was detected in 66/88 (75%) blood donors
who drank alcohol daily tested and in 92/125 (74%) non-alcohol drinkers
(p>0.05). Of the 756 anti-HCV blood donors evaluated, 352 (47%) had
at least one risk factor for HCV infection: 98/352 (27.8%) were IVDU,
96/352 (27.2%) had transfusions, 7/352 (2%) had homosexual contacts;
9/352 (2.6%) had received treatment with acupuncture, 62/352 (17.7%)
had tattoos and 80/352 (22.7%) had more than one risk factor. Among
the 209 blood donors tested for HCV RNA, 25/32 (78%) with tattoos
were HCV RNA-positive and 132/177 (74%) donors without tattoos
were HCV RNA-positive by PCR (p>0.05). Among the 31 patients with
tattoos all (100%) were RIBA–2 positive. In 195 blood donors without
tattoos, 176 (90.2%) were positive to RIBA-2, 9 (4.6%) were negative
and 10 (5.2%) were RIBA-2 indeterminate (p>0.05, Fisher test).
Clinical evaluation. Of 756 anti-HCV positive blood donors, 709
(94%) had no symptoms and 47 (6%) had at least one symptom associated
with hepatic disease. Only 15 (2%) donors reported previous jaundice
and 406 (54%) had hepatomegaly. Splenomegaly was observed in 36/
756 (5%) donors. HCV RNA was detected in 56/77 (72%) donors without
hepatomegaly, in 44/68 (64%) with mild hepatomegaly (0-3 cm) and in
57/64 (89%) with moderate or intense hepatomegaly (>3 cm). There
was a significant correlation between hepatomegaly at clinical evaluation
(liver >3 cm) and HCV RNA positivity. Of 256 donors who underwent
to liver biopsies, chronic hepatitis was present in 85/99 (86%) donors
without hepatomegaly, in 62/83 (82%) with mild hepatomegaly and in
59/74 (80%) with intense hepatomegaly (p>0.05). Portal hypertension
or hepatic insufficiency was present in 3/756 (0.4%) donors.
Abdominal ultrasound (US). Two hundred and thirty seven of 366
(65%) donors had at least one alteration upon US. Steatosis was noted
in 118 (50%), CH in 33 (14%), hepatomegaly or hepatosplenomegaly in
79 (33%) and LC in 7 (3%) of the 237.
Liver biopsy. Two hundred and sixty nine anti-HCV positive donors
underwent to liver biopsy. A normal liver was diagnosed in 4 (1.5%),
chronic hepatitis in 225 (83.5%), steatosis in 9 (3%), liver cirrhosis in 6
(2%), minimal changes in 23 (9%) and other non-related diagnoses in 2
(1%). Of 225 donors with CH, 200 (89%) had CAH which was mild or
moderate in 199 (99.5%) and intense in 1 (0.5%) patient. CPH was
diagnosed in 23/225 (10%) of donors and 2/225 (1%) had CLH.
Table 1 shows that 85.2% of the donors diagnosed with CH by
abdominal ultrasound had chronic hepatitis upon histological
examination. There was a strong correlation between steatosis diagnosed
by US and CH determined by histology. About 86% of the donors with
a normal US had CH upon histological examination. There was no
significant correlation between the US results and chronic hepatitis
diagnosed histologically.
Laboratorial evaluation. Protein electrophoresis showed that 654/
696 (94%) anti-HCV positive donors had normal albumin levels and 42/
696 (6%) had hypoalbuminemia. CH was observed in 16/23 (69.5%)
donors with hypoalbuminemia who underwent liver biopsy. All donors
with hypoalbuminemia had an altered liver histology. There was a
significant positive correlation between hypoalbuminemia and CH
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determined histologically (p<0.05). Hypergammaglobulinemia was seen
in 256/642 (40%) anti-HCV positive donors. Of 131 blood donors who
underwent liver biopsy, 118 (90%) with hypergammaglobulinemia had
chronic hepatitis while 88/114 (77%) donors with normal levels of
gammaglobulins had chronic hepatitis based on histology. There was a
significant positive correlation between gammaglobulin levels and CH
determined histologically (p< 0.05).
Of the 756 anti-HCV positive blood donors, 562 (74.4%) had a
qALT>1 and 194 (25.6%) a qALT≤1. Liver biopsies were done on 269
of these 756 donors, 257 (95.5%) of whom had qALT>1 and 12 (4.5%)
a qALT≤1. A total of 221/257 (86%) donors with qALT>1 had chronic
hepatitis as did in 4/12 (33.4%) donors with a qALT≤1. There was a
significant positive correlation between ALT activity and chronic hepatitis
(p< 0.05).
RIBA-2 and HCV RNA. A total of 226 anti-HCV positive donors
were tested for RIBA-2. Of these 207 (91.6%) were RIBA-2 positive,
10 (4.4%) were negative and 9 (4%) were indeterminate. Of 209 anti-
HCV positive donors tested for HCV-RNA by PCR, 157 (75%) were
HCV RNA-positive and 52 (25%) were negative.
Table 2 shows the RIBA-2 and HCV RNA results in 159 anti-HCV
positive blood donors who underwent a liver biopsy. One hundred and
thirty four out of 152 (88%) RIBA-2 positive donors had CH and 12/
152 (8%) had MC. 4/152 (2.8%) had steatosis, 1/152 (0.6%) had CH
and 1/152 (0.6%) had other diagnoses. One RIBA-2 negative donor had
MC and in six RIBA-2 indeterminate donors 3 (50%) had CH and 3
(50%) had MC. In addition 118/135 (87.4%) PCR-positive donors had
CH while 16/24 (66.7%) cases of CH were noted among HCV RNA-
negative donors. There was a significant positive correlation between
the presence of HCV RNA in serum and chronic hepatitis upon
histological examination (p<0.05).
Among anti-HCV positive donors with a qALT>1, 196 (95.6%) were
RIBA-2 positive, 8 (3.9%) were RIBA-2 indeterminate and 1 (0.5%)
was RIBA-2 negative. Among 21 donors with a qALT≤1, 11 (52.4%)
were RIBA-2 positive, 2 (9.5%) were RIBA-2 indeterminate and 8
(38.1%) were RIBA-2 negative. There was a significant positive
correlation between ALT levels and the results of the RIBA-2 assay
(p<0.05). Among 185 anti-HCV positive donors with a qALT>1, 152
(82%) were HCV RNA-positive and 33 (18%) negative, while among
24 anti-HCV positive donors with a qALT≤1, 5 (21%) were HCV RNA-
positive and 19 (79%) were negative. There was a significant positive
correlation between ALT levels and occurrence of HCV-RNA by PCR.
A total of 192 anti-HCV EIA-2 positive donors were tested for RIBA
and HCV RNA by PCR (Table 3). Among 173 RIBA-2 positive donors,
142 (82%) were HCV RNA-positive and 31 (18%) were negative. Among
11 RIBA-2 negative donors, 1 (9%) was HCV RNA-positive and 10
Table 1
US abdominal alterations and histologic diagnoses in anti-HCV positive blood donors (n=218)
LIVER HISTOLOGY
Chronic Liver Normal Minimal
hepatitis Steatosis Cirrhosis liver changes Others Total
ULTRASOUND n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Chronic hepatitis 23 85.2 1 3.7 1 3.7 1 3.7 1 3.7 - - 27 100
Steatosis 85 86.7 1 1.0 - - - - 12 12.3 - - 98 100
Liver cirrhosis 6 85.7 - - - - - - 1 14.3 - - 07 100
Normal 38 86.4 3 6.8 1 2.2 - - 2 4.6 - - 44 100
Hepatomegaly 19 73.0 1 3.8 - - - - 4 15.6 2 7.6 26 100
Splenomegaly 11 68.8 2 12.5 - - 1 6.2 2 12.5 - - 16 100
Total 182 83.5 8 3.6 2 0.9 2 0.9 22 10.2 2 0.9 218 100
Table 2
RIBA-2 and HCV RNA results for anti-HCV positive blood donors based on the histological diagnosis (n=159).
HISTOLOGICAL DIAGNOSIS
LABORATORIAL Chronic Hepatitis Steatosis Liver Cirrhosis Minimal changes Others
TESTS n % n % n % n % n %
RIBA-2
Positive 134/152 88.0 4/152 2.8 1/152 0.6 12/152  8.0 1/152 0.6
Negative - - - - - -  1/1 100.0 - -
Indeterminate 3/6 50.0 - - - -  3/6  50.0 - -
HCV-RNA
Positive 118/135 87.4 3/135 2.2 2/135 1.5 11/135  8.1 1/35 0.8
Negative  16/24 66.7 1/24 4.1 - -  7/24  29.2 - -
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(91%) were HCV RNA-negative. Among 8 RIBA-2 indeterminate blood
donors, 3 (37.5%) were HCV RNA-positive and 5 (62.5%) were negative.
There was a significant positive correlation between RIBA-2 and the
PCR results (p<0.05).
A total of 582 anti-HCV positive blood donors were tested for HVB
markers. Of these, 58 (10%) were HBsAg negative/anti-HBc total
positive/anti-HBs negative, 86 (15%) were HBsAg negative/anti-HBc
total positive/anti-HBs positive and 23 (4 %) were positive only for anti-
HBs, 415 (71%) were negative for all HBV markers
Donors with chronic hepatitis (CH). Among 225 patients with
chronic hepatitis, 18 (8%) had symptoms of hepatitis, 8 (4%) had previous
jaundice and 179 (80%) denied any contact with icteric persons. Upon
clinical examination, 127 (56%) had hepatomegaly. The spleen was
enlarged in 17/225 (8%) cases. Clinical signs of portal hypertension
were detected in 3/225 (1%) patients. Hypoalbuminemia was detected
in 16 (7%) patients and 118 (52.4%) patients had elevated levels of
gammaglobulins. Abdominal US done in 182 patients diagnosed CH in
23 (13%) and steatosis in 85/182 (47%) (eight cases of steatosis were
also diagnosed among the 23 patients with CH). Thus steatosis was
present in 93/182 (51%) blood donors with chronic hepatitis detected
by US. Cirrhosis was detected by US in 6/182 (3%) cases while 38/182
(21%) had a normal US. Thirty individuals (16%) showed only
enlargement of the liver or spleen. Of 134 patients with CH who were
screened for HCV RNA, 118 (88%) were HCV RNA-positive whereas
among 137 patients with CH tested for RIBA-2, 134 (98%) were positive
and 3 (2%) were indeterminate. In the three patients with CH who were
RIBA-2 indeterminate, only antibody anti-c22-3 was detected. Both
RIBA-2 and HCV-RNA screening were done in 124 patients with CH.
Of these 108 (89%) RIBA-2 positive patients were HCV RNA-positive
while among three RIBA-2 indeterminate patients 2 (66.6%) were HCV
RNA-positive and 1 (33.3%) was HCV RNA-negative.
Among 18 blood donors with minimal changes who were screened
for HCV-RNA 11 (61%) were positive and 7 (39%)were negative. Among
16 tested for RIBA-2, 12 (75%) were positive, 3 (19%) were
indeterminate and 1 (16%) was negative.
DISCUSSION
Among our donors, 95.6% were anti-HCV positive at the second
EIA test and 91.6% were RIBA-2 positive. Even with the improvement
in the sensitivity of second generation tests (anti-HCV EIA-2), false-
positives (negative RIBA-2) are claimed, in other series, to still occur in
40% of the donors tested by EIA (15,85). The low number of false-
positive cases among our donors perhaps reflects the fact that we only
evaluated anti-HCV in individuals with an EIA-2 ratio >3 (highly
positive). At least one risk factor for HCV was detected in 47% of the
donors. Blood transfusion and drug abuse were the principal risk factors
for the acquisition of HVC. The use of drugs is frequently denied by
blood donors8. In one study of RIBA positive blood donors, who denied
the use of IV drugs in their initial interview at a blood bank, subsequently
42% admitted this practice in the past when interviewed a second time2,8.
In some cases, previous use of drugs is not considered as risk factor for
the future transmission of HCV. The intravenous use of tonics, containing
glucose and vitamins, is widely spread in Brazil, including among some
sportsmen. As these substances are not considered drugs, they are not
reported in the blood banks interviews. A small number of donors (2%)
admitted having a homosexual relationship. Among the 96% of donors
who reported heterosexual behavior, 16% had multiple partners. In fact,
the interviews at blood banks generally exclude donors with risky sexual
behavior more easily than IVDU.
Some authors had reported no association between previous treatment
with acupuncture or tattooing and an increase in HCV transmission8. Only
3% of our donors had undergone acupuncture and 18% had tattoos.
Tattooing was not associate with a greater frequency of viremia (p>0.05)
or greater positivity in the RIBA test, but was associated with more frequent
drug addiction. Alcohol abusers with chronic hepatopathies have a high
positivity for anti-HCV with 65%-94% showing HCV RNA21. We also
detected 75% of our donors who were alcohol abusers were positive for
HCV RNA, which also happened in 74% of the non-alcoholists.
There was a significant correlation between intense hepatomegaly
at physical examination and greater positivity for HCV RNA in the serum
of our donors. However, there was no association between hepatomegaly
and chronic hepatitis upon the histological examination. For this reason,
hepatomegaly was not considered indicative of the need for liver biopsies
among anti-HCV positive donors.
Steatosis is a histological marker for chronic hepatitis caused by HCV
and when observed at US of anti-HCV positive donors with an EIA ratio >3
may be indicative of that disease. Although US diagnosed only 14% of our
donors as having chronic hepatitis, all of them were viremic. In most cases,
the diagnosis of CH by US agreed with the histological results (85.2% of
donors) (Table1). Only 3.7% of the donors with US suggesting CH had a
normal histological result. The presence of normal liver in US was not
correlated with histological findings because about 86% of these donors
showed CH upon histology. In some situations, US provided additional
information which allowed a better clinical evaluation of these donors.
Histological examination revealed light or moderate chronic hepatitis
in most donors (83.5%) with a few individuals who were histologically
normal (1.5%) or had hepatic cirrhosis (2%). This confirmed the need
of a hepatic biopsy in these anti-HCV positive donors. Other reports
have shown that HCV RNA-positive donors always have chronic
hepatitis, with the lesions being light or moderate in 87% of the cases
and intense in 13%2. Among the HCV RNA positive donors evaluated
here, 89% had CH or cirrhosis, 2.2% had steatosis, 8% showed minimal
changes and 0.8% had portal fibrosis (Table 2). In agreement with others
studies2, no HCV RNA positive donor had a normal histological result.
Among our donors HCV RNA positivity was a predictive factor for
chronic hepatitis upon histological examination.
Table 3
RIBA-2 and HCV-RNA results in anti-HCVpositive blood donors (n=192)
HCV-RNA (PCR)
RIBA-2  Positive  Negative  Total
 n  %  n  %  n (%)
Positive 142  82.0 31  18.0 173 100.0
Negative  1  9.0 10  91.0  11 100.0
Indeterminate  3  37.5  5  62.5  8 100.0
Total 146  76.0 46  24.0 192 100.0
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The median age of our donors was 33.7 years old. A high frequency
of advanced histological lesions was not expected since these usually
appear after 20-30 years of HCV infection2. This is also applied to the
hypoalbuminemia. Only 6% of donors showed hypoalbuminemia and
of these, 70% had histologic diagnosis of CH (p<0.05). In 40% of the
donors was observed hypergammaglobulinemia resulted from alterations
caused by HCV and not from cirrhosis, considering the mild hepatic
involvement observed here. There was a significant positive correlation
between hypoalbuminemia or hypergammaglobulinemia and the
frequency of CH in the histological sections of the donors.
In our study, 91.6% of the anti-HCV positive donors were also RIBA-2
positive. This proportion is greater than the 36% of RIBA-2 positive cases
reported in similar individuals in studies conducted in Italy16,19 and France22
and the 39% observed in the USA13. In Spain, 33-63% of anti-HCV positive
donors were also RIBA-2 positive17,20. The discrepancy between our results
and these cited above may be related to the type of donor included in our
avaliation (EIA ratio >3). Of the anti-HCV donors tested, 75% were HCV
RNA positive. In Italy, in the USA and in Spain the frequency of HCV RNA
positivity was 66%, 58% and 63%, respectively, among RIBA-2 positive
and indeterminate donors13,16,20. In a recent compilation15 62% of RIBA-2
positive or indeterminate donors were HCV RNA positive, a frequency
slightly lower than that observed here among our donors (75%) with an
EIA ratio>3 and high positivity for RIBA-2.
About 74% of our donors had elevated ALT levels. Other authors,
have observed that 69% of RIBA-2 positive donors have increased serum
ALT levels8. Considering the anti-HCV positive donors with a qALT>1,
95.6% were RIBA-2 positive compared to 52.4% of RIBA-2 positive
donors with a qALT<1 (p<0.05). Based on the histological results, a
liver biopsy was always recommended in anti-HCV positive donors with
an EIA ratio >3, independent of the results of confirmatory exams. Among
RIBA-2 indeterminate donors who underwent a liver biopsy, 50% had a
histological diagnosis of chronic hepatitis and 50% showed a liver with
minimal changes. In a recent study, RIBA-2 indeterminate donors were
reported to be indeterminate or positive when tested by RIBA-3 and that
30% were positive for HCV RNA11. For this reason, we considered as
obligatory to screen RIBA indeterminate patients for HCV RNA.
HCV RNA levels are generally lower in patients with normal values
of ALT6 and this could explain the low detection of viral RNA among
our donors with a normal ALT (21%). On the other hand, HCV RNA
was detected in 82% of anti-HCV positive donors with a qALT>1. The
HCV RNA negativity in 18% of the donors with a high qALT can reflect
the absence of the virus, inherent problems with the test or an increase
in ALT attributable to non-viral causes.
The frequency of viremia among 192 anti-HCV positive donors
screened for RIBA and PCR was 76% (146/192) with 19% (36) having
only antibodies against HCV (RIBA-2 positive or indeterminate) indicating
probably cured cases of HCV. The frequency of false-positives for HCV
(RIBA-2 and HCV RNA-negative) was 5.2% (10/192) (Table 3). False
negatives for HCV RNA generally occur in patients with viral loads below
the limit of detection of the PCR assay used25 or following the occurrence
of intermittent viremias18. The potentially infective nature of all RIBA-2
positive donors with a negative PCR should be borne in mind. Our
frequency of 14% (31/192) for RIBA positive and PCR negative patients
was similar to that reported by others4, who noted that patients infected by
HCV recovered from the acute infection, eradicated the virus spontaneously
and remained HCV RNA negative for several years1.
Eighty nine percent of the HCV RNA positive donors had hepatic
lesions associated with a chronic HCV infection (87.5% had a histological
diagnosis of chronic hepatitis and 1.5% had hepatic cirrhosis) (Table 2).
The remaining 11% were patients with minimal changes, perhaps because
they were cases of initial chronic hepatitis C. On the other hand, 67% of
HCV RNA negative donors showed chronic hepatitis upon histological
examination (Table 2).
Close to one third (29%) of the anti-HCV positive donors were
positive for at least one marker of a past infection for hepatitis B virus.
HBV and HCV are thought to attack these populations sequentially or
simultaneously3,10.
Most donors with a histological diagnosis of chronic hepatitis were
symptomless (92%) and only 4% reported past jaundice. This pattern is
characteristic of this infection. In patients with a post-transfusional HCV
infection, jaundice has been detected in 19%-26% of the patients in the
acute phase10,24. Besides the few symptoms, donors with chronic hepatitis
usually show mild hepatomegaly with a few cases of intense
hepatomegaly (7%) or splenomegaly (8%); only 1% show signs of portal
hypertension or hepatic insufficiency. Hypoalbuminemia was detected
in only 7% our patients and reflected the mildly compromised function
hepatic present in these still young donors with HCV. US detected chronic
hepatitis in 13% of the patients with the above histological diagnosis,
but diagnosed steatosis in 47% of patients with CH based on histological
examination. Since steatosis is an etiologic marker of chronic HCV, US
identified, directly or indirectly, about 60% of individuals that could
have chronic hepatitis. For this reason we stipulated that anti-HCV
positive donors with US results showing hepatic steatosis, should undergo
a liver biopsy, to confirm chronic hepatitis. For individuals with histologic
results showing minimal changes, 87% had increased serum ALT levels,
61% were positive for HCV RNA, 75% were positive for RIBA-2 and
19% were RIBA-2 indeterminate. In these cases, a complete laboratorial
investigation is needed to diagnose the HCV infection.
Finally, we consider that the clinical, epidemiological, laboratorial,
histological and ultrasonographical features observed among our blood
donors anti-HCV EIA-2 reagent with EIA ratio >3 are very similar and
representative of the observed among patients with chronic hepatitis C
histologically confirmed. A high proportion of these donors could be
identified in interviews and medical evaluation performed in the medical
screening of the blood blanks, because they had clinical and
epidemiological evidences for HCV infection. Generally, these HCV
infected donors are identified and discharged only by the serological
tests results, showing that the medical procedures realized in routine of
blood banks are inadequate.
RESUMO
Avaliação clínica, epidemiológica, laboratorial, histológica e
ultrassonográfica de doadores de sangue anti-HCV EIA-2
positivos
Entre 1992 e 1997 foram avaliados, ambulatorialmente, 790 doadores
de sangue com teste anti-HCV EIA-2 fortemente reagente (relação entre
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a densidade ótica da amostra / “cut-off” > 3), que haviam sido detectados
na triagem sorológica do banco de sangue. Todos eram negativos para
doença de Chagas, sífilis, hepatite B (HBsAg) e AIDS. Amostras de
sangue foram coletadas, na primeira consulta ambulatorial, para a
realização de hemograma, exames bioquímicos e novos testes sorológicos
para a HVC (anti-HCV EIA-2). Em 226 doadores anti-HCV EIA-2
repetidamente reagentes, realizou-se o teste suplementar de
“immunoblot” para a HVC (RIBA-2). Em 209 doadores, pesquisou-se a
presença do RNA do VHC pelo teste do PCR, através de exame
automatizado (HCV-AMPLICOR, ROCHE). A ultra-sonografia
abdominal foi realizada em 366 doadores e a biópsia hepática em 269
concordantes.
Notou-se que 95,6% eram EIA-2 repetidamente reagentes, 94% eram
assintomáticos e que apenas 2% referiram icterícia pregressa. Em 47%
detectou-se, pelo menos, um fator de risco para a transmissão do VHC,
sendo o uso de drogas E.V. o principal deles (27,8%). A transfusão de
sangue foi o segundo fator na transmissão da HVC (27,2%).
Hepatomegalia foi encontrada em 54%. Esplenomegalia e sinais de
hipertensão portal foram raramente encontrados no exame físico,
denotando o baixo grau de comprometimento hepático na HVC. A ultra-
sonografia abdominal mostrou-se alterada em 65% dos indivíduos, sendo
a esteatose a alteração mais freqüentemente observada (50%).
Em 83,5% dos doadores submetidos à biópsia hepática, diagnosticou-
se hepatite crônica, geralmente classificada como ativa (89%) e de grau
leve ou moderado na maioria dos casos (99,5%). O histopatológico foi
normal em 1,5% dos doadores. O teste de RIBA-2 e a pesquisa do RNA
do VHC pelo PCR foram positivos em, respectivamente, 91,6 e 75%
dos doadores anti-HCV EIA-2 reagentes. A pesquisa do RNA do VHC
foi positiva em 82% dos indivíduos RIBA-2 reagentes, em 37,5% dos
doadores RIBA-2 indeterminados e em 9% dos RIBA-2 negativos.
Hepatite crônica foi observada em 50% dos doadores RIBA-2
indeterminados. Entre 18 doadores com alterações mínimas, ao exame
histopatológico, 11 (61%) eram positivos para o RNA do VHC. Nossos
doadores de sangue anti-HCV reagentes geralmente apresentam
alterações clínicas, laboratoriais e histopatológicas próprias de pacientes
com hepatites crônicas pelo VHC e uma elevada proporção destes podem
ser identificados em entrevistas e avaliação médicas rotineiramente
realizadas em bancos de sangue. Geralmente estes doadores infectados
pelo VHC somente são identificados e bloqueados pelos resultados dos
testes sorológicos.
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